Epigenomics Valuation Multiples

Epigenomics Overview

About Epigenomics

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Founded

1998

HQ

Employees

2

Website

epigenomics.com

Sectors

Medical Imaging & DiagnosticsMedical DevicesDiagnostics & GenomicsHealthTech

Financials (FY)

Revenue: —

EBITDA: $1M

EV

$13M

Valuation Multiples

Multiples.vc

Start free trial

Epigenomics Financials

Epigenomics reported last fiscal year revenue of — and EBITDA of $1M.

In the same fiscal year, Epigenomics generated — in gross profit, $1M in EBITDA, and had net loss of ($4M).

Epigenomics P&L

In the most recent fiscal year, Epigenomics reported revenue of — and EBITDA of $1M.

Epigenomics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Epigenomics Stock Performance

Epigenomics has current market cap of $961K, and enterprise value of $13M.

Epigenomics' stock price is $1.10.

Epigenomics Valuation Multiples

Epigenomics trades at 9.9x EV/EBITDA.

Epigenomics Financial Valuation Multiples

As of April 20, 2026, Epigenomics has market cap of $961K and EV of $13M.

Equity research analysts estimate Epigenomics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Epigenomics has a P/E ratio of (0.2x).

Epigenomics Margins & Growth Rates

Epigenomics' revenue in the last fiscal year declined by (100%).

Epigenomics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.

Epigenomics Public Comps

See public comps and valuation multiples for other Medical Imaging & Diagnostics and Medical Devices comps.

Epigenomics M&A Activity

Epigenomics acquired XXX companies to date.

Last acquisition by Epigenomics was on XXXXXXXX, XXXXX. Epigenomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Epigenomics Investment Activity

Epigenomics invested in XXX companies to date.

Epigenomics made its latest investment on XXXXXXXX, XXXXX. Epigenomics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).